Celgene, Abide reshuffle partnership

Celgene Corp. (NASDAQ:CELG) gained exclusive, worldwide rights to preclinical candidate ABX-1772 from Abide Therapeutics Inc. (San Diego, Calif.), and the companies terminated a

Read the full 234 word article

User Sign In